Products Categories
CAS No.: | 64241-34-5 |
---|---|
Name: | HYDRAZINECARBOXYLIC ACID, 2-[6-[ETHYL(2-HYDROXYPROPYL)AMINO]-3-PYRIDAZINYL]-, ETHYL ESTER |
Article Data: | 4 |
Molecular Structure: | |
Formula: | C12H21 N5 O3 |
Molecular Weight: | 283.33 |
Synonyms: | CGP 18684E;Cadral; Cadralazine; Cadraten; Cadrilan; DC 826; ISF 2469; Presmode |
Density: | 1.253 g/cm3 |
Melting Point: | 160-162° |
Boiling Point: | 425.88°C (rough estimate) |
Safety: | Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx. |
PSA: | 99.61000 |
LogP: | 1.22060 |
What can I do for you?
Get Best Price
Chemistry informtion about Cadralazine (CAS NO.64241-34-5) is:
IUPAC Name: Ethyl N-[[6-[Ethyl(2-Hydroxypropyl)Amino]Pyridazin-3-Yl]Amino]Carbamate
Synonyms: Hydrazinecarboxylic Acid, 2-[6-[Ethyl(2-Hydroxypropyl)Amino]-3-Pyridazinyl]-, Ethyl Ester ; Cadralazine ; Cadral ; Cadraten ; Cadrilan ; Cgp 18684e ; Dc 826 ; Isf 2469
MF: C12H21N5O3
MW: 283.33
Density: 1.253 g/cm3
Following is the molecular structure of Cadralazine (CAS NO.64241-34-5) is:
Raw materials are Ethyl carbazate-->Amino-2-propanol-->Phthalazine .
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | 400mg/kg (400mg/kg) | cardiac: change in rate vascular: bp lowering not characterized in autonomic section kidney, ureter, and bladder: changes in blood vessels or in circulation of kidney | Journal of Cardiovascular Pharmacology. Vol. 3, Pg. 455, 1981. |
dog | LD50 | oral | > 2gm/kg (2000mg/kg) | Drugs of the Future. Vol. 7, Pg. 382, 1982. | |
mouse | LD50 | intraperitoneal | 362mg/kg (362mg/kg) | Drugs of the Future. Vol. 7, Pg. 382, 1982. | |
mouse | LD50 | intravenous | 162mg/kg (162mg/kg) | Drugs of the Future. Vol. 7, Pg. 382, 1982. | |
mouse | LD50 | oral | 825mg/kg (825mg/kg) | Drugs of the Future. Vol. 7, Pg. 382, 1982. | |
mouse | LD50 | subcutaneous | 1420mg/kg (1420mg/kg) | sense organs and special senses: ptosis: eye behavioral: altered sleep time (including change in righting reflex) lungs, thorax, or respiration: dyspnea | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 3839, 1987. |
rat | LD50 | intraperitoneal | 440mg/kg (440mg/kg) | Drugs of the Future. Vol. 7, Pg. 382, 1982. | |
rat | LD50 | intravenous | 269mg/kg (269mg/kg) | cardiac: change in rate vascular: bp lowering not characterized in autonomic section | Journal of Cardiovascular Pharmacology. Vol. 3, Pg. 455, 1981. |
rat | LD50 | oral | 2060mg/kg (2060mg/kg) | cardiac: change in rate vascular: bp lowering not characterized in autonomic section | Journal of Cardiovascular Pharmacology. Vol. 3, Pg. 455, 1981. |
rat | LD50 | subcutaneous | > 2gm/kg (2000mg/kg) | sense organs and special senses: ptosis: eye behavioral: altered sleep time (including change in righting reflex) liver: other changes | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 3839, 1987 |
Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx.
Cadralazine (CAS NO.64241-34-5) is an antihypertensive of the hydrazine chemical class.